Trikafta access in India: the CDSCO Rule 36 named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Trikafta is the Vertex Pharmaceuticals triple-combination CFTR modulator approved by the US FDA in October 2019 for cystic fibrosis patients aged 2 years and older who carry at least one F508del mutation in the CFTR gene. Trikafta does not currently hold routine CDSCO marketing authorisation in India for commercial distribution. India CF advocacy and the dialogue between patient groups and Vertex on Indian registration and pricing have moved through public statements and litigation tracks, and the broader registration question remains contested while families and physicians continue to ask for a structured pathway. In the meantime, the legitimate route for an Indian family whose physician has decided Trikafta is the next step runs through Rule 36 personal-import on Form 12A and Form 12B, or through institutional Compassionate Use at a Centre of Excellence under the National Policy for Rare Diseases. Reserve Meds operates as a documented cross-border named-patient channel pending the broader registration resolution.

Reserved for you.

Why families in India reach for Trikafta through NPP

India has the largest tertiary specialty hospital network of any Reserve Meds priority country, and Indian manufacturers supply a significant share of the world's generic medicines. For US originator specialty products like Trikafta, however, three patterns of access gap recur. A drug can be registered with CDSCO but the specific brand, strength, or pack size is not stocked in the dispensing pharmacy on the day therapy is meant to start. A drug can be registered for one indication and prescribed for another FDA-approved use that is not on the Indian label. A drug can be FDA-approved in the United States but not registered locally at all because the originator manufacturer has not pursued Indian marketing authorisation. For Trikafta the dominant pattern is the third: the product is FDA-approved and registered across most regulated markets, but does not currently have routine CDSCO marketing approval in India for commercial distribution.

The named-patient case for Trikafta also rests on the molecule. Roughly 90 percent of people with cystic fibrosis carry at least one F508del allele, which is the eligibility gate for Trikafta. The pediatric label was extended to ages 6 and older in June 2021, then to ages 2 and older in April 2023, broadening the population of Indian children eligible for the drug. India CF advocacy groups and individual families have engaged Vertex and the Indian regulatory and judicial system on the broader access question. Public reporting and court filings have documented this dialogue across several years, and that dialogue is still live. While the broader registration question is contested, the Rule 36 personal-import permit is a separately documented legal route for a named patient under the Drugs and Cosmetics Rules 1945, and Reserve Meds frames its role within that route, not outside it.

The CDSCO named-patient pathway for Trikafta

The legal foundation for personal import of unregistered medicines into India is Rule 36 of the Drugs and Cosmetics Rules 1945. Rule 36 permits import of small quantities of a drug, whose import would otherwise be prohibited under Section 10 of the Drugs and Cosmetics Act 1940, for the exclusive personal use of a named patient. Form 12A is the application for the permit. Form 12B is the permit itself, issued by the office of the Drugs Controller General of India (DCGI) at FDA Bhawan, Kotla Road, New Delhi, or by designated CDSCO Port Offices. The application is accompanied by a prescription from a Registered Medical Practitioner (RMP) showing the RMP's National Medical Commission registration number and the quantity required for treatment. The quantity of any single drug imported shall not exceed one hundred average doses per application.

For institutional Compassionate Use of drugs not approved for marketing in India at all, the parallel pathway is the Compassionate Use application route to the DCGI by a government hospital, a registered medical practitioner, a pharmaceutical company, or the patient. This route applies when the drug is approved by a recognised reference authority (FDA, EMA, MHRA, Health Canada, PMDA) for a life-threatening condition, a serious permanent disability, or an unmet medical need. AIIMS, Tata Memorial Centre, and other tertiary institutions have established workflow for this route. For pediatric CF, the Centres of Excellence designated under the National Policy for Rare Diseases 2021 are also natural homes for compassionate access discussions.

For Trikafta the clinical-justification angle is genotype-specific. A complete CDSCO application typically includes:

• A clinical justification letter naming the patient's CFTR genotype (at least one F508del mutation, or another responsive variant on the current FDA label), the diagnosis, prior modulator history if any, and the reason this specific product is required
• The treating physician's NMC registration number and a copy of state council registration where required
• A patient identifier and supporting medical records, including the genetic-testing report
• Product details: Trikafta, elexacaftor 100 mg / tezacaftor 50 mg / ivacaftor 75 mg morning tablet and ivacaftor 150 mg evening tablet (or the appropriate pediatric strength or granule packet), manufacturer Vertex Pharmaceuticals, pack size, quantity (not to exceed one hundred average doses per application)
• The dispensing facility's drug licence (hospital pharmacy or specialty importer's wholesale licence)
• A chain-of-custody plan from the US specialty-pharmacy source to the dispensing pharmacy in India

CDSCO's published guidance states the Form 12B permit issues on a priority basis, typically within one to two days for routine applications where the documentation is complete. In practice families plan for a two to four week window from physician decision to dispensed medicine, because the bulk of the elapsed time is upstream documentation assembly and downstream international logistics rather than the regulator stamp.

Where Trikafta gets dispensed in India

Trikafta is an oral therapy. There is no infusion-centre requirement, no cold-chain, and the dispensing footprint is broader than for biologics. Tertiary hospitals with established import-pharmacy infrastructure handle Trikafta as routine workflow. Institutions that file named-patient imports as established practice include the All India Institute of Medical Sciences (AIIMS) in New Delhi, Tata Memorial Centre in Mumbai (anchor of the National Cancer Grid but with parallel rare-disease and pediatric specialty programmes), Apollo Hospitals (Chennai flagship, with Delhi, Bangalore, Hyderabad, and Kolkata), Fortis Memorial Research Institute in Gurgaon and the Fortis Mulund, Bangalore, and Kolkata sites, Medanta in Gurgaon, Kokilaben Dhirubhai Ambani Hospital in Mumbai, MGM Healthcare in Chennai, Christian Medical College (CMC) in Vellore, and Manipal Hospitals in Bangalore.

For pediatric CF cases the natural homes are the pediatric pulmonology and rare-disease services at AIIMS Delhi (also a designated Centre of Excellence under the National Policy for Rare Diseases), the pediatric services at Apollo Chennai and Apollo Delhi, CMC Vellore's pediatric programme, and the pediatric service at Kokilaben Mumbai. Families in tier 2 cities without a local CF centre typically route to one of these centres for the prescription and clinical justification letter, then work with a CDSCO-licensed specialty importer in Mumbai, Delhi, or Bangalore that files the Form 12A and handles chain-of-custody documentation. The importer carries the CDSCO relationship and the customs-broker relationship; Reserve Meds aligns with the importer on US-side sourcing and with the treating physician on clinical documentation.

Real cost picture for Trikafta in India

US wholesale acquisition cost for Trikafta is approximately USD 322,000 per patient per year, which works out to roughly USD 26,800 per month for adult-strength dosing. ICER's 2020 review described this list price as well above a cost-effective threshold and characterised Vertex's pricing posture as monopoly-tier. That history is the backdrop to the price advocacy Indian CF families have engaged in. The named-patient acquisition cost sits between US WAC and confidential negotiated payer prices in markets like the United Kingdom, France, and Germany, and is finalised only on firm-quote issuance after document review.

The Indian rupee floats against the US dollar. In May 2026 the USD/INR rate sits in the 94 to 95 range, with the rupee having weakened modestly against the dollar over the prior twelve months. Monthly drug acquisition at US WAC translates to roughly INR 25 lakh to INR 26 lakh per month at the prevailing rate. International logistics for Trikafta runs at the lower end of the Reserve Meds lane range, typically USD 400 to USD 800 (approximately INR 38,000 to INR 76,000), because the product is ambient-controlled rather than cold-chain. India's Union Budget 2026-27 expanded the list of life-saving drugs and rare-disease drugs eligible for customs duty exemption, and the specific HSN code and exemption status for any Trikafta shipment is confirmed at the documentation stage. GST on most life-saving medicines is 5%.

On the insurance side, Star Health and Allied Insurance, HDFC ERGO, ICICI Lombard, and Niva Bupa each handle named-patient imports case by case; none reimburse a Rule 36 personal import as a standard line item. CGHS provides for life-saving drugs not in the standard formulary to be considered by an Expert Committee under Special DG (DGHS) case by case, with stricter constraints on drugs not approved by the DCGI. Cash-pay is the default posture. The National Policy for Rare Diseases provides for one-time financial assistance with a current ceiling of INR 50 lakh per patient for rare diseases requiring one-time treatment, which is meaningful but typically falls short of the lifetime cost of chronic CFTR modulator therapy.

Typical timeline for Trikafta in India

For an established Trikafta candidate with a clean F508del genotype letter, a current weight-band confirmation, and a CF-centre referral, the typical end-to-end cycle is 2 to 4 weeks. CDSCO published guidance puts the Form 12B priority window at 1 to 2 days for complete routine documentation. US-side sourcing through the Vertex specialty-pharmacy network adds roughly 1 to 2 weeks. International ambient-controlled transit and Indian customs clearance under the import permit at Delhi, Mumbai, Bangalore, Chennai, or Hyderabad airport are typically 3 to 7 days. First-time imports through a smaller importer, or cases routed through a Centre of Excellence under the Compassionate Use route rather than Rule 36, can extend the front end. Trikafta is room-temperature stable, so timelines are not pinched by cold-chain logistics. Timelines are presented as typical ranges and not as promises; specific dates are confirmed at firm-quote issuance.

What your physician needs to provide

The clinical justification letter for Trikafta is the centrepiece of the CDSCO package. For this product the letter typically includes:

• The patient's confirmed cystic fibrosis diagnosis and CFTR genotype (at least one F508del allele documented on the genetic-testing report, or another responsive variant on the current FDA label)
• The patient's current age and weight, with the weight band that determines the appropriate Trikafta strength (adult strength for patients aged 12 and older or pediatric patients 25 kg and above; lower-strength tablet for patients 6 to 11 under 25 kg; granule packets for patients ages 2 to 5 in two weight bands at 10 kg and 14 kg thresholds)
• Prior CF treatment history and any prior CFTR-modulator exposure (Kalydeco, Orkambi, Symdeko, or Trikafta itself)
• Justification for why a locally registered alternative is not suitable, which for Trikafta is typically the absence of a clinically equivalent on-label alternative in India
• The dosing plan: morning tablet plus evening tablet 12 hours apart, both with fat-containing food (ivacaftor absorption increases roughly three-fold with dietary fat)
• The monitoring plan: baseline and periodic liver function tests (ALT, AST, bilirubin) every three months for the first year then annually; baseline and follow-up ophthalmologic examination in pediatric patients for cataracts; medication reconciliation for CYP3A interactions (rifampin and St John's wort contraindicated, strong inhibitors requiring dose reduction)
• The PvPI adverse-event reporting plan as part of the Pharmacovigilance Programme of India obligation

The treating physician's NMC registration number must appear on the prescription. State-council registration is required for practice in a particular state. Specialty hospital physicians at AIIMS, Tata Memorial, Apollo, Fortis, Medanta, Kokilaben, MGM, CMC Vellore, and Manipal routinely sign these letters as part of established institutional workflow.

Common questions about Trikafta in India

What does the contested registration status mean for my family? The Rule 36 personal-import permit is a separately documented legal route under the Drugs and Cosmetics Rules 1945, and it operates regardless of whether the broader registration discussion between Vertex and the Indian regulatory or judicial system has concluded. Reserve Meds frames its role within that documented permit route. The broader access conversation is a separate track that Indian CF advocacy organisations are continuing to engage on.

Will Star Health, HDFC ERGO, ICICI Lombard, or Niva Bupa cover Trikafta? Each plan handles named-patient imports case by case. None of the major private insurers reimburse a Rule 36 personal import as a standard line item. Some have reimbursed full or partial drug cost when the underlying medicine is on their formulary; for Trikafta, which does not currently hold routine CDSCO marketing approval, that pathway is narrower. We supply the documentation set that lets your insurer assess the case. Cash-pay is the default posture.

Will CGHS or ESIC cover Trikafta? CGHS provides for life-saving medicines not in the standard formulary to be considered by an Expert Committee under Special DG (DGHS), case by case. Drugs not approved by the DCGI face a stricter Expert Committee review, which applies to Trikafta. ESIC's formulary is narrower and not structured for routine personal-import reimbursement. Check eligibility with your CGHS Wellness Centre or the ESIC dispensary before assuming coverage.

Will the National Policy for Rare Diseases cover Trikafta? The NPRD provides one-time financial assistance with a current ceiling of INR 50 lakh per patient for rare diseases requiring one-time treatment. The ceiling and the one-time framing are widely understood to fall short of the full lifetime cost of chronic CFTR modulator therapy. Families with NPRD eligibility may apply for partial cost coverage; the application sits with the Centre of Excellence.

What if my child is under 2 years old? Trikafta is approved for patients aged 2 years and older. Reserve Meds will not coordinate intake for a patient outside the FDA-approved age range.

What about Alyftrek? Alyftrek (vanzacaftor, tezacaftor, deutivacaftor) is Vertex's once-daily successor approved by the FDA in December 2024. Trikafta has longer real-world experience, broader international registration, established payer pathways, and lower acquisition cost in several markets. Switching is a clinician-driven decision and not one Reserve Meds makes.

What is the safety profile? Most common adverse events on the pivotal trials were headache, upper respiratory infection, abdominal pain, rash, and elevated transaminases. Drug-induced liver injury, cataracts in pediatric patients, and hypersensitivity reactions are labeled warnings. Baseline and periodic liver function testing and pediatric ophthalmologic examination are part of the monitoring plan.

Where Reserve Meds fits in Trikafta cases

Reserve Meds is a US-based concierge coordinator. We do not replace your CF physician, do not replace CDSCO, and do not replace the dispensing pharmacy or the licensed importer. For Trikafta specifically we orchestrate the US-side sourcing through the Vertex specialty-pharmacy network, the regulatory documentation kit your physician needs for Form 12A (genotype letter template, dosing reference by weight band, monitoring plan summary, PvPI reporting reference), international ambient-controlled logistics under chain-of-custody, and a single named coordinator who carries the family from intake through delivery and into the reporting period. F508del genotype documentation, CF-centre referral letter, and current weight-band confirmation are mandatory intake artefacts. We operate as a legitimate Rule 36 channel pending the broader registration discussion between Vertex, Indian regulators, and the courts. We do not coordinate off-label use, and we will decline intake for patients without at least one F508del allele or another labeled CFTR-responsive variant.

Next step

If your CF physician has decided Trikafta is the right next step and local registration or stocking is the bottleneck, the Rule 36 personal-import pathway through CDSCO is the route. Join the waitlist below and we will confirm eligibility within 24 to 48 hours and route the documentation kit to your physician.

Join the Trikafta waitlist

Reserved for you.